LaDuane Clifton, MBA, CPA

R. LaDuane Clifton, MBA, CPA, has extensive public company, global finance, operations, and strategic leadership, with 35+ years in transformational roles within the biopharmaceutical development and commercialization, global electronics manufacturing, and managed care industries. As a member of the executive management team at Transpire Bio, he is responsible for the company’s global finance, investor relations, and capital formation activities. Prior to joining Transpire Bio, Mr. Clifton served as Chief Financial Officer and Treasurer of Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage rare disease therapeutics company. Previously, roles include Chief Financial Officer, Secretary, and Treasurer of The LGL Group, Inc., and Chief Financial Officer of a21, Inc. Earlier in his career, Mr. Clifton was an auditor at KPMG LLP, and held finance and healthcare contracting roles at Aetna, Inc. Transpire Bio Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio is innovating by applying its deep inhalation drug formulation and delivery expertise to respiratory and systemic diseases where currently available options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry-powder inhalers and soft mist inhalers, and is progressing a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson’s Disease Psychosis, and Glioblastoma.